AZD9773 Dose Escalation Study
Public ClinicalTrials.gov record NCT00615017. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Placebo-controlled, Double-blind, Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients With Severe Sepsis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a double-blind, placebo-controlled, multi-center, dose-escalation study to assess the safety, tolerability, Pharmacokinetics and Pharmacodynamics of single and multiple ascending intravenous infusions of CytoFab (AZD9773) in adult patients with severe sepsis.
Study identification
- NCT ID
- NCT00615017
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 70 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2008 (Type not available)
- Primary completion
- Jul 2009 (Actual)
- Completion
- Jul 2009 (Actual)
- Last update posted
- Aug 22, 2013
2008 – 2009
United States locations
- U.S. sites
- 26
- U.S. states
- 16
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | — | — |
| Research Site | Newark | Delaware | — | — |
| Research Site | Bay Pines | Florida | — | — |
| Research Site | Miami | Florida | — | — |
| Research Site | Chicago | Illinois | — | — |
| Research Site | Oak Park | Illinois | — | — |
| Research Site | Peoria | Illinois | — | — |
| Research Site | Indianapolis | Indiana | — | — |
| Research Site | Iowa City | Iowa | — | — |
| Research Site | Hazard | Kentucky | — | — |
| Research Site | Lexington | Kentucky | — | — |
| Research Site | Baltimore | Maryland | — | — |
| Research Site | Kansas City | Missouri | — | — |
| Research Site | Camden | New Jersey | — | — |
| Research Site | Newark | New Jersey | — | — |
| Research Site | Brooklyn | New York | — | — |
| Research Site | New York | New York | — | — |
| Research Site | Rochester | New York | — | — |
| Research Site | Durham | North Carolina | — | — |
| Research Site | Greensboro | North Carolina | — | — |
| Research Site | Winston-Salem | North Carolina | — | — |
| Research Site | Columbus | Ohio | — | — |
| Research Site | Oklahoma City | Oklahoma | — | — |
| Research Site | Nashville | Tennessee | — | — |
| Research Site | Galveston | Texas | — | — |
| Research Site | Houston | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00615017, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 22, 2013 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00615017 live on ClinicalTrials.gov.